iwCLL Program

Friday, 20 September
7:30 – 16:30
Young Investigator Meeting
19:00 – 21:00 iwCLL Welcome Reception at the
Edinburgh Castle
Saturday, 21 September
08:15 Welcome and Introductions
Opening Remarks
Peter Hillmen
08:30 History of CLL
Gerald Marti
THEME 1: BIOLOGY AND PATHOPHYSIOLOGY
Session 1:
The CLL (Epi)genome
08:45 Overview of the CLL Genome
Jonathan Strefford
09:05 The Epigenetic Features of CLL:
DNA Methylation
Christoph Plass
09:25
Insights From Tertiary Structure, Chromatin
Modifications, and Nuclear Organization
José Ignacio Martín-Subero
09:45 Selected Abstracts
10:15 Morning Break
Session 2:
The CLL (Epi)genome (cont.)
10:45 Keynote
Evolution and Mathematical Modelling of
Cancer Genomes
Gad Getz
11:15 Functional Implications of Genomic Lesions
Catherine Wu
11:35
The Impact of Regulatory RNA Molecules
Marek Mráz
11:55 ATM: Pathway, Lesions, and Targeting
Tatjana Stankovic
12:15 Selected Abstracts
12:45
Lunch
Session 3: The B-Cell Receptor
13:45 Role of the B-Cell Receptor in B-Cell
Oncogenesis
Stefano Casola
14:15
Dissecting CLL Immunogenetics and
Emerging B-Cell Receptor Stereotypes
Kostas Stamatopoulos
14:35 CLL-Specific Aspects of B-Cell Receptor
Signaling
Graham Packham
14:55 Selected Abstracts
15:25
Afternoon Break
Session 4: Microenvironment and Models of CLL
15:55 Linking the Microenvironment With CLL
Models
Nicholas Chiorazzi
16:15
In Vitro Modelling of the CLL
Microenvironment
Alan Ramsay
16:35 Murine and Xenograft Models of CLL
Shih-Shih Chen
16:55 Role of NOTCH1 in CLL and in Richter’s Transformation
Silvia Deaglio
17:15
Selected Abstracts
17:45 End of day 1
Sunday, 22 September
THEME 2: INNOVATIONS IN THE ASSESSMENT OF CLL
Session 1:
 
08:15 Laboratory Assessment of CLL, Including MRD
as an End Point
Andrew Rawstron
08:35 Molecular Characterization of CLL
Richard Rosenquist Brandell
08:55 Clinical Assessment of CLL
Carol Moreno
09:15 Critical Assessment and New Development of
Prognostic Scoring Systems
Barbara Eichhorst
09:35
Selected Abstracts
10:05 Morning Break
THEME 3: THERAPY
Session 1:
Initial Therapy
10:30 Keynote
Overview of Clonal Evolution and Genomic Instability in CLL and implications for therapy
Daniel Landau
11:00 Early Intervention: Can We Justify It and What
End Points Should We Consider?
Petra Langerbeins
11:20 Current Initial Treatment of CLL – for Young
Patients
Florence Cymbalista
11:40 Current Initial Treatment of CLL – for Elderly
Patients
Valentin Goede
12:00 Treatment of CLL From 2019 Onwards:
Overview of Recent Phase 3 Trials
TBD
12:40 Selected Abstracts
13:10 Lunch
Janssen Oncology supported satellite symposium
14:00 Start Time
15:25
Afternoon Break
Session 2:
Clonal Evolutions and Resistance
Mechanisms
15:45 Development of Resistance to B-Cell Receptor
Inhibition
Jennifer Woyach
16:05 Development of Resistance to BCL2 Inhibition
Mary Ann Anderson
16:35
Selected Abstracts
17:00
Binet/Rai Medal Presentation
17:15
Poster Session Reception
19:00
End of day 2
Monday, 23 September
Session 3:
Therapy of Relapsed/Refractory CLL
08:15 B-Cell Receptor-Inhibitor Therapy in Relapsed/
Refractory Disease
Susan O’Brien
08:35 BCL2-Inhibitor-Based Therapy and MRD in
Relapsed/Refractory Disease
John Seymour
08:55 Novel Combinations and MRD in Relapsed/
Refractory Disease
Matthew Davids
09:15 Defining Duration of Therapy: Is There a Role
for MRD?
Talha Munir
09:35
Selected Abstracts
10:05
Morning Break
10:35 Evolution of Small Molecule Inhibitors:
New vs Old
John Byrd
10:55 Updates on Immune Therapy Strategies,
Including CAR T-Cell Therapy and Stem Cell
Transplant
Katy Rezvani
11:15
Selected Abstracts
11:45 Debate: Future Management of CLL:
Is There a Role for Cellular Therapy?
Moderator: Anna Schuh
David Maloney (CAR T)
Johannes Schetelig (SCT)
Matt Davids (Novel-Novel)
12:30
Lunch
Session 4:
Real-World Data and Registries
13:15 CLL Clinical Genomics: Overview of the
National Programmes in Sweden, the US, the
UK, and France
Anna Schuh
13:30 Geographic Diversity and Management of CLL
in South American Patients
Carlos Sérgio Chiattone
13:45 Geographic Diversity and Management of CLL
in African Patients
Norah Akinola
14:00 Geographic Diversity and Management of CLL
in Indian Patients
Abraham Varghese
14:15 Geographic Diversity and Management of CLL
in Chinese Patients
Shenmiao Yang
14:30
Selected Abstracts
14:45
Afternoon Break
iwCLL UPDATES
Chair: Peter Hillmen
15:15 Current Efforts From European and US
Real-World Data
Christopher Fox (EU) and Anthony Mato (US)
15:45 An Update From the European Research
Initiative on CLL (ERIC)
Paolo Ghia
16:15
Reorganization of the iwCLL
Michael Hallek
16:45
Closing Comments
Peter Hillmen
17:00 Close of Workshop

– Agenda subject to change